Trials / Terminated
TerminatedNCT01955733
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 82 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 695500 |
Timeline
- Start date
- 2013-05-31
- Primary completion
- 2015-11-18
- Completion
- 2016-11-07
- First posted
- 2013-10-07
- Last updated
- 2018-01-18
- Results posted
- 2018-01-18
Locations
43 sites across 9 countries: United States, Belgium, Bulgaria, Germany, Greece, Netherlands, Poland, Portugal, Spain
Source: ClinicalTrials.gov record NCT01955733. Inclusion in this directory is not an endorsement.